Boy with Drum, painting by Rodolfo Amoedo

The Drumbeat for Amycretin Grows Louder in Obesity

As the upcoming Scientific Sessions for the American Diabetes Association draws closer, the drumbeat for amycretin as a promising new therapy for obesity is growing louder. At the meeting, Novo Nordisk plans to present two different studies to strengthen the case for this novel dual agonist. It targets both GLP-1 and amylin receptors.

Then yesterday the company announced plans to plunge into pivotal trials for this drug in both oral and injectable forms early next year. Martin Lange, Executive Vice President for Development, said:

“We are very pleased that the feedback from regulatory authorities has allowed us to take subcutaneous and oral amycretin in weight management to phase 3. We are excited about the amycretin molecule, and this marks an important step forward. ”

Moving to Recover Leadership

This is the latest in a series of moves by Novo to project that the company is serious about retaining leadership in obesity care innovation. Previously, it had told the world that CagriSema would be the next great leap forward, but when the company released topline results for this combination drug, investors yawned. With that yawn came a big drop in the stock price.

With amycretin, Novo has one molecule to target both receptors – GLP-1 and amylin – that CagriSema targets with a combination of two drugs. By no means does this mean Novo has given up on CagriSema. But it does mean that they have a backup if CagriSema continues to disappoint. Stay tuned for the results on both drugs coming next week at the ADA meeting.

We might see that amycretin will exceed the expectations of the drug for which it had been an understudy.

Click here, here and here for more on amycretin.

Boy with Drum, painting by Rodolfo Amoedo / WikiArt

Subscribe by email to follow the accumulating evidence and observations that shape our view of health, obesity, and policy.


 

June 14, 2025